MedTrace Logo

Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia

NCT04613271 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2023-03-08

No results posted yet for this study

Summary

The benefit of the research is to provide information regarding the efficacy and safety of Favipiravir plus the Standard of Care (SoC) for mild-moderate COVID-19 patients to be a reference for policy recommendations regarding the use of Favipiravir as an antiviral drug for the treatment of Covid-19.

Conditions

Interventions

DRUG

Favipiravir

Assignment of Administration Group 1: Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.

DRUG

Azithromycin

Azithromycin 500 mg once a day for 5 days.

Sponsors & Collaborators

  • Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia

    collaborator UNKNOWN

  • Ina-Respond

    lead OTHER

Principal Investigators

  • Dr. dr. Armedy Ronny Hasugiana, M. Biomed, MD · Center for R & D of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2021-10-25
Completion
2021-11-08

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04613271 on ClinicalTrials.gov